Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.

and the published evidence on effective management of asthma, so they are equipped to provide reliable information and optimal treatment for their patients," wrote GINA on their official website.

The Global Initiative for Asthma (GINA) and the National Asthma ... Patients had a mean age of 41 years, and 41% were male. Median treatment duration of the included RCTs was 26 weeks.